Tom has 35 years of global sales and marketing experience in the diagnostics sector. He most recently worked for Alere Inc. in Africa for 11 years before retiring in 2017. At Alere he held a range of executive posts including President of Africa, President Commercial Operations for Africa, and Business Development Director for Africa; and led the introduction and successful commercialisation of a number of key HIV screening and HIV patient management point of care diagnostics technologies.
Prior to joining Alere Inc., Tom held senior commercial roles at Trinity Biotech (Ireland) including Marketing and Sales Director (Global) and Business Development Director for Africa, Middle East and India. Trinity Biotech specialises in the development, manufacture and marketing of diagnostic test kits.
Tom studied Microbiology at Glasgow Caledonian University and completed a National Diploma in Microbiology at the South African Institute of Medical Research in Johannesburg, South Africa.
Ian Gilham, Non-Executive Chairman of genedrive, said: “Tom has exceptionally strong experience in commercialising diagnostics in Africa and other low and middle income markets. We look forward to working with him as we continue to deliver on the opportunities presented by our Genedrive® HCV ID test, which is the first decentralised test to market, and by the Genedrive® platform more widely.”
Tom Lindsay said: “The simplicity, low-cost, speed and versatility of the Genedrive® platform represent significant strengths for decentralised molecular diagnostics. I am excited to join the Board and about the prospects for Genedrive® across multiple indications and markets.”
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
Full name and age: Thomas Lindsay (aged 60)
Tom Lindsay does not currently hold any shares in genedrive plc.
Current Directorships or Partnerships:
None
Previous Directorships or Partneships in the last five years:
Alere Healthcare Pty Ltd
Pantech Pty Ltd
Alere Nigeria Ltd
Vision Biotech Pty Ltd
No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.
